Targeting PD-1 post-translational modifications for improving cancer immunotherapy.

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Programmed Cell Death Protein 1 (PD-1) is an immune checkpoint receptor crucial for immune suppression via PD-L1 interaction.
• Tumors utilize the PD-1/PD-L1 axis to evade immune surveillance, leading to the development of immune checkpoint inhibitors.
• Current limitations in PD-1/PD-L1 blockade effectiveness stem from an incomplete understanding of underlying regulatory mechanisms.

Purpose of the Study:

• To review recent findings on the role of Programmed Cell Death Protein 1 (PD-1) post-translational modifications (PTMs).
• To explore emerging therapeutic strategies targeting PD-1 PTMs for enhanced cancer immunotherapy.
• To provide mechanistic insights for advancing combination cancer immunotherapies.

Main Methods:

• Literature review focusing on recent research findings.
• Analysis of studies investigating PD-1 post-translational modifications (PTMs) such as ubiquitination, UFMylation, phosphorylation, palmitoylation, and glycosylation.
• Examination of pre-clinical and clinical data on therapeutic strategies targeting PD-1 PTMs.

Main Results:

• Various PTMs critically regulate PD-1 stability, localization, and interactions.
• Dysregulation of PD-1 PTMs contributes to immune evasion and resistance to cancer therapies.
• Targeting PD-1 PTMs with small molecules or antibodies shows promise in preclinical models and clinical trials.

Conclusions:

• Understanding PD-1 PTMs is essential for overcoming limitations in current cancer immunotherapies.
• Modulating PD-1 PTMs represents a promising therapeutic avenue to enhance anti-tumor immunity.
• Integrating knowledge of PD-1 PTMs can facilitate the rational design of more effective combination cancer immunotherapies.